Company Description
EPIEN Medical is a specialty medical devices company that is developing products for treatment of oral inflammation and acute and chronic wounds based on our chemical formulations that act as aggressive desiccation and debriding agents.
We refer to this proprietary process as Desiccation Shock Technology (“DST”). Eleven published clinical trials have shown that our products reduce and, very often, eliminate the need for antibiotics to treat topical infectious wounds, including oral infections and open infectious wounds.
Standard treatments can take months and even years of daily antibiotic use to heal an open infectious wound.
Our DST enables our easy-to-use, topically applied products to desiccate harmful bacteria in seconds.
In 2021, our HYBENX and ERADX product lines received 510(k) clearance from the U.S. Food and Drug Administration, as a medical device for use as an adjunctive rinse of tooth root surfaces during periodontal debridement procedures.
In 2013, the European Regulatory Agency cleared our HYBENX and ERADX product lines for the same uses.
We plan to initiate a “de novo” classification request with the FDA for our REVITY product candidate for treatment of chronic wounds in the first quarter of 2023.
Our KONKURE product line also uses our proprietary DST in the oral veterinary market.
| Country | United States |
| Founded | 1991 |
| Industry | Health Care |
| Sector | Health Care Equipment & Supplies |
| Employees | 13 |
| CEO | Reginald R. Dupre |
Contact Details
Address: 600 Highway 169 South, Suite 820 St. Louis Park, MN 55426 United States | |
| Phone | (651) 653-3380 |
| Website | epien.com |
Stock Details
| Ticker Symbol | EPMI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001881672 |
| Employer ID | 41-1710238 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Reginald R. Dupre | Chief Executive Officer and Chairman of the Board |
| David A. Ufheil | Chief Financial Officer |
| Michael L. Basara, M.D. | Executive Vice President, Research and Development |
| Steven J. Kavros, DPM | Chief Medical Officer and VP of Regenerative Medicine |
| Jonathan B. Dodge, CPA | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2023 | RW | Filing |
| Sep 30, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 4, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jan 19, 2022 | DRS | [Cover] Draft Registration Statement |
| Sep 13, 2021 | D | Notice of Exempt Offering of Securities |